14 results
Drugs for Heart Failure

#medications #chf #pathophysiology #cardiology #pharmacology
medications #chf #pathophysiology ... #cardiology #pharmacology
Cardiovascular effects of intravenous infusion of Epinephrine, Norepinephrine and Isoproterenol

#Epinephrine #Norepinephrine #Isoproterenol #Pharmacology #Cardiovascular #Effects #Pathophysiology
Isoproterenol #Pharmacology ... Cardiovascular #Effects #Pathophysiology ... #Cardiology
Childhood Immunization Schedule: Why we immunize
 • Diphtheria Toxin -> URT inflammation causes pseudomembrane with hardened
Tetanus Toxin -> Spores ... Fecal-oral route, virus ... shock • Mumps Virus ... lymph -> Koplik's spots ... peds #pediatrics #pathophysiology
Medications Used in Congestive Heart Failure

In CHF, the heart is failing as a pump; cardiac output
output on a short-term ... #Pharmacology #CHF ... #HeartFailure #Cardiology
Remdesivir (GS-5734) - manufactured by Gilead Sciences
Remdesivir blocks the replication of viruses by inserting into the
replication of the virus ... #Remdesivir #Pharmacology ... #Pathophysiology
Iron Deficiency in Congestive Heart Failure (CHF)

Iron deficiency (ID) in heart failure is a common comorbidity
#Failure #CHF #pharmacology ... #pathophysiology ... #cardiology
Digoxin Pharmacology and Pathophysiology
1) Na/K ATPase Pump - Digoxin works by directly binding to and inhibiting
Digoxin Pharmacology ... and Pathophysiology ... CaitEKulig #Digoxin #Pharmacology ... #Pathophysiology ... #cardiology
Antiarrhythmics - Vaughan Williams Classification:
CLASS 1 - Sodium Channel Blockers:
 • MOA: Block fast Na+ channels
inotropy) ACCP Cardiology ... Vaughan #Williams #Pharmacology ... Classification #Classes #pathophysiology ... #cardiology
Antiarrhythmics Pharmacology Summary
Cardiac Conduction Phases:
Phase 0 - Ventricular Depolarization:
 • Na+ channels open leading to a
Antiarrhythmics Pharmacology ... inotropy) ACCP Cardiology ... Antiarrhythmics #Pharmacology ... Classification #Classes #pathophysiology ... #phases #cardiology
Guillain-Barre Syndrome - Summary

Acute AIDP that presents with rapidly progressive flaccid weakness

Epidemiology:
 • 1-2 cases/100,000 per
Guillain-Barre Pathophysiology ... COVID 19 - Zika virus ... • Weakness: Starts